One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Aldeyra Therapeutics, Inc.
ALDX · NCM · Healthcare · Biotechnology
Current price
$1.21
52-week range
$1.07 - $5.93
Market cap
$72.69M
Balance sheet
Healthy
-18.51x Concerning
Net cash $44.95M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -49.5% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 3.6% (peer median: 5.1%).
What this company does
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a biotechnology company developing new medicines for diseases caused by an overactive immune system, such as severe dry eye disease. Because its main drugs are still in clinical trials (the required process of testing new treatments on people for safety and effectiveness), the company does not yet have significant sales and relies on funding from investors to operate. The company's future success depends on whether its drugs pass these final tests and receive government approval to be sold to patients.
How the company got here
Aldeyra Therapeutics was founded in 2004 with a specific scientific idea: that controlling harmful molecules called 'reactive aldehyde species' could be a new way to treat diseases caused by inflammation. For its first decade, the company worked on developing this science. A key turning point came in 2014 when Aldeyra became a public company through an IPO (Initial Public Offering, the first time a company sells its stock to the public), which gave it the money needed to run expensive clinical trials (studies in people to test if a drug is safe and effective). This funding allowed the company to focus its efforts on developing treatments for eye diseases, which became its primary area of research.
What it actually does
Aldeyra Therapeutics is a biotechnology company that works to discover and develop new medicines for diseases where the body's own immune system is out of balance. It doesn't sell any products yet, as its potential medicines are still being tested in clinical trials to see if they work and are safe. The company's main approach is creating drugs that trap and neutralize harmful molecules in the body known as RASP (reactive aldehyde species), which are linked to inflammation. Its most talked-about potential products are an eye drop called reproxalap for common conditions like dry eye disease, and an injection called ADX-2191 for very rare and serious eye diseases.
Developing Novel Drugs
The company operates as a single business focused entirely on researching and developing new medicines. Since its potential drugs are still in the testing phase, Aldeyra does not yet have any sales revenue (money from selling products). Its business runs on money raised from investors, and it spends this cash on research and on clinical trials, which are the required multi-step studies to prove a drug is safe and effective enough for approval by regulators like the U.S. Food and Drug Administration (FDA). The company's value is based on the potential for these experimental drugs to one day become approved, prescribed medicines.
What management is betting on now
The company's main strategy is to prove that its unique scientific approach of targeting RASP molecules can lead to successful, approved drugs. Their biggest immediate bet is on getting their lead drug candidate (a potential medicine in the final stages of testing), an eye drop named reproxalap, approved for treating dry eye disease and allergic conjunctivitis. The company is also heavily invested in developing ADX-2191, a specialized injection for rare but serious retinal diseases that currently have no approved treatments. Looking further ahead, management is using its scientific platform to create a pipeline (a portfolio of drugs in development) of next-generation medicines for other inflammatory conditions.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-5.45M
Diluted EPS
-0.09
Operating cash flow
$-4.59M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.45M
Diluted EPS
-0.06
Operating cash flow
$-5.11M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.46M
Diluted EPS
-0.10
Operating cash flow
$-5.30M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-7.69M
Diluted EPS
-0.13
Operating cash flow
$-7.02M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-9.77M
Diluted EPS
-0.16
Operating cash flow
$-8.56M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-9.93M
Diluted EPS
-0.17
Operating cash flow
$-12.47M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-15.81M
Diluted EPS
-0.27
Operating cash flow
$-12.04M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-15.11M
Diluted EPS
-0.25
Operating cash flow
$-7.97M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.21
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $44.9M - more cash than debt. Interest coverage -18.5x.
Net debt
$-44.95M
Interest coverage
-18.51x
Aldeyra Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ALDX
BASELINE
Aldeyra Therapeutics, Inc.
Total debt $143.45K Interest coverage -18.51x This is the baseline the peer rows are being compared against.
Total debt $333.02K Interest coverage -473.91x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -11.91x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ALDX
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -49.5% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 3.6% (peer median: 5.1%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-4.38x
P/B
1.92x
P/S
—
EV/EBITDA
-1.17x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-49.5%
ROA
-22.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
4.91x
Quick ratio
4.67x
Total debt
$143.45K
Total cash
$45.09M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-0.38
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-22.02M
Free CF TTM
$-33.35M
FCF margin
—
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—